Optimization of Dupilumab Maintenance Dosing in Eosinophilic Esophagitis: A Phase IV, Randomized, Controlled, Single-Blind, Non-Inferiority Study
Eosinophilic oesophagitis (EoE) is an allergic condition that causes swelling in the oesophagus (the gullet or food pipe), making swallowing painful and difficult. The medicine dupilumab is an effective treatment that helps calm this inflammation. This Phase 4 study is testing whether adults who are already doing well on dupilumab can safely reduce their maintenance dose and still remain in remission over 52 weeks (one year). Researchers want to see if a lower dose works just as well as the standard dose. During the trial, doctors will track participants' swallowing symptoms, check their overall quality of life, and look at the food pipe using camera tests (endoscopies) and tissue samples. The goal is to help doctors tailor long-term treatment, potentially reducing medicine use and side effects while keeping the condition firmly under control.
At a glance
What is this study about?
Eosinophilic oesophagitis, or EoE, is a chronic allergic condition where white blood cells cause inflammation in the lining of the food pipe. This swelling can make it feel like food is getting stuck when you swallow, which can be distressing and uncomfortable. Dupilumab is a modern biological medicine that targets the root cause of this allergic reaction, helping the food pipe heal and relieving symptoms.
While dupilumab works well to bring EoE into remission, doctors want to know the best way to keep it under control over the long term. Currently, patients often take the same standard dose indefinitely. This study is exploring dose 'optimisation'—checking whether patients can step down to a lower or less frequent maintenance dose without their symptoms or inflammation returning.
Finding the lowest effective dose is important because it could mean fewer injections, lower costs for healthcare services like the NHS, and a smaller chance of long-term side effects. By carefully monitoring participants over 52 weeks with regular health checks and camera inspections of the gullet, researchers hope to give doctors clear evidence on how to safely tailor dupilumab treatment for each person.
Key takeaways
- The trial tests whether a reduced maintenance dose of dupilumab can safely keep EoE in remission.
- It is designed for adults aged 18 and over who have eosinophilic oesophagitis.
- Participation lasts for 52 weeks (one year) with regular hospital monitoring.
- Tests include symptom questionnaires, blood tests, and endoscopies with small biopsies.
- You can withdraw from the study at any time without affecting your normal healthcare.
Who may be eligible?
This trial is open to adults aged 18 and older who have been diagnosed with eosinophilic oesophagitis. Because the study focuses on long-term maintenance, participants will generally be people whose condition has already responded well to dupilumab and is currently in remission.
Both men and women can take part. However, this trial may not be suitable for people who are pregnant or breastfeeding, or those who have other serious medical conditions that could make the medicine or study tests unsafe.
A doctor or research nurse will review your medical records and perform routine health checks to ensure that joining the study is safe and appropriate for your individual situation.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you aged 18 or older?
- Have you been diagnosed with eosinophilic oesophagitis (EoE)?
- Are you currently taking dupilumab or eligible to receive it?
- Is your condition currently well-controlled or in remission?
- Are you willing and able to attend clinic visits and have camera checks (endoscopies) over a 12-month period?
What does participation involve?
Taking part in this study lasts for 52 weeks (one year). You will receive dupilumab as a maintenance treatment, which is given by injection under the skin. Your dosing schedule will be set according to the study plan. Over the year, you will attend regular hospital appointments for check-ups, blood tests, and questionnaires about your symptoms and daily wellbeing. Doctors will also carry out camera checks of your food pipe (endoscopies) to collect small tissue samples (biopsies) to see if the lining remains healthy. The clinical team will support you throughout the trial and monitor your health closely.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is dupilumab?
Dupilumab is a targeted medicine given by injection that blocks specific chemical signals in the body responsible for allergic inflammation in conditions like EoE.
What does 'maintenance dosing' mean?
Maintenance dosing refers to the regular, long-term dose of medicine taken to keep an illness from returning once it has already been brought under control.
Will I know which dose I am receiving?
This is a single-blind trial, which usually means the study doctors know your dose, but you may not be told right away to ensure the study results remain completely unbiased.
What happens if my swallowing symptoms return?
Your safety comes first. If your symptoms worsen or your inflammation comes back, the study team will step in promptly and adjust your treatment back to standard care.
Do I have to pay to take part?
No, all study-related treatments, clinic appointments, and tests are provided without charge, and help with travel expenses is often available.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.